Skip to Main Content
Our Commitment to Diversity

Highlights From FDA Regulatory Developments in Clinical Trials: 2023 Recap and 2024 Forecast

Share via LinkedIn
Share via Twitter
Share via Facebook
Date: 5 March 2024
Triage
By: Rebecca M. Schaefer, Michael H. Hinckle, Elisabeth M. Lewis

In this episode, Rebecca Schaefer, Michael Hinckle, and Elisabeth Lewis summarize FDA regulatory developments from 2023 and what to expect in 2024 as it relates to clinical research. They discuss the significance of the decentralized clinical trials guidance documents, highlights of the Informed Consent Guidance document, the impacts of FDA’s final rule on IRB waivers of consent, the IRB review of individual patient expanded access submissions, and the potential effects of the new proposed rule for lab developed tests.

Find more items tagged as: Health Care, Health Care and FDA, Health Care Transactions, Hospitals and Health Systems, Policy and Regulatory
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel